Tat

F.W. Webb Moves Boston Wholesale Location and Frank Webb Home Showroom into New Facility

Retrieved on: 
Monday, January 22, 2024

Webb Company is pleased to announce that its Boston wholesale store and Frank Webb Home showroom have moved into a new facility at 101 Hampden Street , which is conveniently located just off Route 93.

Key Points: 
  • Webb Company is pleased to announce that its Boston wholesale store and Frank Webb Home showroom have moved into a new facility at 101 Hampden Street , which is conveniently located just off Route 93.
  • The new facility is adorned with a mural completed by the legendary Bronx-based graffiti artists Tats Cru.
  • Local artists Kem5 and Deme helped with the art project at the new Boston facility.
  • At the brand-new Frank Webb Home showroom, working displays will offer a hands-on experience while knowledgeable showroom consultants will be available to showcase their expertise in bath, kitchen, and lighting solutions.

Cellectar Biosciences Broadens Pipeline with Targeted Alpha Therapy (TAT) for Solid Tumors and Releases Promising Preclinical Data

Retrieved on: 
Tuesday, January 16, 2024

FLORHAM PARK, N.J., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced promising preclinical data for its proprietary novel alpha-emitting phospholipid radiotherapeutic conjugate, CLR 121225 (225Ac-CLR 121225) an actinium-labeled phospholipid ether (PLE), in pancreatic cancer models. The development of this compound will expand the company’s clinical pipeline of PLE cancer targeting compounds to include targeted alpha therapies (TATs), complementing its beta-emitting phospholipid radiotherapeutic conjugate, iopofosine I 131, which achieved its primary endpoint in the CLOVER WaM pivotal study in highly refractory Waldenstrom’s macroglobulinemia patients.

Key Points: 
  • Cellectar’s PLE platform may provide unique advantages which overcome the issues experienced by existing TAT delivery platforms.
  • “Our promising preclinical data with actinium-225 highlights the potential utility of our PLE platform to provide targeted delivery to nearly any isotope resulting in compounds with excellent activity and tolerability.
  • The mice had no end organ toxicities demonstrating good tolerability.
  • The data are consistent with experiments using other alpha emitters conjugated to the company’s proprietary PLE targeted delivery platform.

Scramble for the Sahel – why France, Russia, China and the United States are interested in the region

Retrieved on: 
Monday, January 8, 2024

In the last decade, issues such as terrorism, insecurity and trafficking have characterised the region.

Key Points: 
  • In the last decade, issues such as terrorism, insecurity and trafficking have characterised the region.
  • Military takeovers have been a major source of concern in the region and beyond in the last few years.
  • This is because Niger was seen as a “darling of the west” and a model for democratic governance in the region.
  • The main actors in this scramble are the European Union, France, Russia, China and the United States.


availability of natural resources
strategic location of the region in Africa
economic interests of the countries involved in the scramble
defence and security cooperation in the form of arms sales.
Foreign powers all have their reasons to be involved in the scramble for the Sahel.

France

  • Unlike Britain, France has maintained strong links with former colonies.
  • Despite these cracks, France is keen to maintain its grip on these countries, especially pertaining to military cooperation and resource extraction.
  • France was reluctant to pull its military out of Mali, Burkina Faso and Niger despite the countries severing military partnerships.

Russia

  • More recently, the emphasis by western countries on human rights, especially during counterterrorism operations, has pushed Sahelian countries closer to Russia.
  • While western allies demand the rule of law, democracy, and human rights in return for security and economic support, Russia portrays itself differently.
  • Furthermore, the Wagner group, the controversial private military company which is controlled by Russia, cooperates with some countries in the Sahel.

China

  • Like Russia, China portrays itself as an alternative to the traditional ally (France) of Sahelian countries.
  • With a mantra of “non-interference” and “respecting sovereignty”, China has entrenched itself as a “partner” of countries in the Sahel.
  • China is keen to use the conflicts in the Sahel to test its arms products.

The United States

  • A year before that, I had written about the security implications of the base for the region.
  • Unlike France and China, which both have extensive economic interests in the Sahel, the US has a strong military interest.
  • Niger, in particular, is strategically located and the US can easily fly surveillance and reconnaissance drones from the country to cover the Sahel, west and central Africa.


Olayinka Ajala does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

Fusion Pharmaceuticals Announces Clinical Program and Manufacturing Updates

Retrieved on: 
Thursday, January 4, 2024

In February 2023, Fusion acquired an IND for the ongoing Phase 2 clinical trial (the TATCIST trial) evaluating FPI-2265 (225Ac-PSMA I&T).

Key Points: 
  • In February 2023, Fusion acquired an IND for the ongoing Phase 2 clinical trial (the TATCIST trial) evaluating FPI-2265 (225Ac-PSMA I&T).
  • Fusion announced today encouraging early findings from Cohort 2 in the ongoing FPI-1434 Phase 1 clinical trial.
  • Fusion reported today that it has completed validation of its state-of-the-art good manufacturing practice (GMP) manufacturing facility and produced the first clinical dose of a TAT.
  • We built Fusion on a foundation of end-to-end manufacturing expertise, including experience with global radiopharmaceutical logistics and distribution.

BWXT Medical Expands Collaboration with Fusion Pharmaceuticals Through Strengthened Actinium Supply and Access to Generator Technology

Retrieved on: 
Thursday, November 16, 2023

Under the agreement, BWXT Medical (a subsidiary of BWX Technologies, Inc. (NYSE: BWXT)), will provide Fusion with a preferential supply of radium-225 and access to high-specific activity generator technology (actinium-227-free), enabling Fusion to produce actinium-225 at its Good Manufacturing Practice (GMP) manufacturing facility for the benefit of its clinical trials.

Key Points: 
  • Under the agreement, BWXT Medical (a subsidiary of BWX Technologies, Inc. (NYSE: BWXT)), will provide Fusion with a preferential supply of radium-225 and access to high-specific activity generator technology (actinium-227-free), enabling Fusion to produce actinium-225 at its Good Manufacturing Practice (GMP) manufacturing facility for the benefit of its clinical trials.
  • BWXT’s proprietary generator technology allows for the on-demand isolation of high purity actinium-225 from the radium supplied by BWXT Medical.
  • BWXT Medical’s innovative actinium-225 generator technology will have significant benefits for both clinical and future commercial supply.
  • Under that agreement, BWXT Medical has been providing predetermined amounts of Fusion's actinium supply needs at volume-based pricing.

Fusion Pharmaceuticals to Present Interim Data from Phase 1 Trial of FPI-1434 in Patients with Solid Tumors Expressing IGF-1R

Retrieved on: 
Monday, June 26, 2023

HAMILTON, ON and BOSTON, June 26, 2023 /PRNewswire/ --  Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the presentation of interim data from the dose escalation portion of the Phase 1 trial of [225Ac]-FPI-1434 (FPI-1434) in patients with solid tumors expressing IGF-1R. The data will be presented by Neeta Pandit-Taskar, M.D., of Memorial Sloan Kettering Cancer Center, tomorrow at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting and will include molecular imaging, safety and pharmacokinetics (PK) from two dosing regimens: one with FPI-1434 alone ("hot only"), and another in which a small dose of cold antibody (naked IGF-1R antibody without the isotope) is administered prior to each dose of FPI-1434 ("cold/hot"). The poster presentation is available via the SNMMI Annual Meeting mobile application.

Key Points: 
  • "Antibody drug conjugates (ADCs) have shown tremendous success recently, driven in part by the benefits of using more potent payloads.
  • The Phase 1, multi-center, open-label clinical trial is designed to investigate the safety, tolerability and pharmacokinetics of FPI-1434 in patients with solid tumors expressing IGF-1R.
  • The trial is also designed to establish the maximum tolerated dose for FPI-1434 and the recommended Phase 2 dose.
  • To access the live call, please dial 1-877-870-4263 (U.S.), 1-855-669-9657 (Canada) or 1-412-317-0790 (international) and reference Fusion Pharmaceuticals.

Perspective Therapeutics to Present at the 2023 Annual Society for Nuclear Medicine and Molecular Imaging Conference

Retrieved on: 
Thursday, June 8, 2023

RICHLAND, WASHINGTON & CORALVILLE, IOWA, June 08, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents and an innovator in seed brachytherapy treatment options for multiple cancers, today announced it will have four presentations at the 2023 Annual Society for Nuclear Medicine and Molecular Imaging (SNMMI) Conference being held in Chicago from June 24-27, 2023.

Key Points: 
  • RICHLAND, WASHINGTON & CORALVILLE, IOWA, June 08, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents and an innovator in seed brachytherapy treatment options for multiple cancers, today announced it will have four presentations at the 2023 Annual Society for Nuclear Medicine and Molecular Imaging (SNMMI) Conference being held in Chicago from June 24-27, 2023.
  • "Our team at Perspective Therapeutics continues to make progress across all aspects of development, including the generation of promising clinical data.
  • We are delighted to present the latest research on our products at the SNMMI annual conference.
  • This will be a presentation of the initial First-in-Human data from Perspective’s MC1R-targeted VMT01/02 imaging study conducted at the Mayo Clinic, Rochester.

Perspective Therapeutics to Present at the 2023 International Symposium on Radiopharmaceutical Sciences (iSRS)

Retrieved on: 
Wednesday, May 24, 2023

RICHLAND, WASHINGTON & CORALVILLE, Iowa, May 24, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents and an innovator in seed brachytherapy treatment options for multiple cancers, today announced it will be presenting three posters at the 2023 International Symposium on Radiopharmaceutical Sciences (iSRS) Annual Meeting being held in Hawaii from May 22-26, 2023.

Key Points: 
  • "We are thrilled to present our latest research on targeted alpha therapies at the Society of Radiopharmaceutical Sciences annual meeting.
  • We believe that targeted alpha therapies have the potential to revolutionize cancer treatment, and we are committed to advancing this promising new approach."
  • said Thijs Spoor, Perspective Therapeutics’ Chief Executive Officer.
  • This enables the best possible isotopes to be utilized to keep moving us toward the goal of improved cancer therapies.

Fusion Pharmaceuticals Announces Opening of Radiopharmaceutical Manufacturing Facility to Produce Targeted Alpha Therapies for Cancer

Retrieved on: 
Tuesday, May 2, 2023

HAMILTON, ON, May 2, 2023 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the opening of its state-of-the-art radiopharmaceutical manufacturing facility. The 27,000 square foot good manufacturing practice (GMP) compliant facility, which is located adjacent to the Company's research and development labs, has clinical and commercial manufacturing scale capabilities designed to support the Company's growing pipeline of targeted alpha therapies (TATs).

Key Points: 
  • HAMILTON, ON, May 2, 2023 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the opening of its state-of-the-art radiopharmaceutical manufacturing facility.
  • The 27,000 square foot good manufacturing practice (GMP) compliant facility, which is located adjacent to the Company's research and development labs, has clinical and commercial manufacturing scale capabilities designed to support the Company's growing pipeline of targeted alpha therapies (TATs).
  • "Manufacturing and supply chain are critical components of radiopharmaceutical development and commercialization.
  • The new manufacturing facility, part of a 15-year lease agreement with Hamilton, Ontario-based McMaster University, was built by McMaster and equipped and validated by Fusion.

Cellectar Reports Financial Results for Year Ended 2022 and Provides a Corporate Update

Retrieved on: 
Thursday, March 9, 2023

FLORHAM PARK, N.J., March 09, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted treatments for cancer, today announced financial results for the year ended December 31, 2022 and provided a corporate update.

Key Points: 
  • FLORHAM PARK, N.J., March 09, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted treatments for cancer, today announced financial results for the year ended December 31, 2022 and provided a corporate update.
  • Presented preclinical data on the CLR 12120 series of targeted alpha therapies (TATs) at the 13th Annual World ADC Conference.
  • Net cash used in operating activities during the year ended December 31, 2022 was approximately $25.2 million.
  • Research and Development Expense: R&D expense for the year ended December 31, 2022 was approximately $19.2 million, compared to approximately $17.6 million for the year ended December 31, 2021.